Manifold MarketsSin KYCDatos de resolución verificadosCalibración aceptablePronóstico comunitario actualNo 68.1%
Pronosticadores
6
Tipo de pregunta
binary
Metodología
Play-money forecasting platform
Tipo de fuente
Pronóstico
Datos de mercado
Actualizado hace 1 hora
Retrasado4 sept 25, 22:10 UTC31 dic 29, 23:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
Will MDMA-assisted therapy for PTSD be approved by the FDA before 2030?
Manifold MarketsWill a vaccine for HIV be approved by the FDA by 2030?
Manifold MarketsWill a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Manifold MarketsBefore January 1st, 2030, will any treatment for celiac disease be approved by the FDA?
Manifold MarketsWhen will the FDA reclassify BPC-157 to Category 1?
KalshiEbola pandemic in 2026?
PolymarketReglas
Resolution criteria
- Resolve YES if, by 11:59:59 pm Eastern Time on December 31, 2029, the U.S. FDA grants any marketing authorization for human use (approval, licensure, De Novo grant, or 510(k) clearance) to a product that fits this definition: a living, multicellular construct assembled ex vivo from animal or human cells, engineered to perform autonomous tasks in vivo (e.g., locomotion/drug delivery)—i.e., a “xenobot/biobot/anthrobot”-type product.
- Verification must appear in one of the FDA’s public databases: Drugs@FDA (NDAs/BLAs), Purple Book (licensed biologics), PMA, De Novo, or 510(k).
- Links: Drugs@FDA, Purple Book, PMA, De Novo, 510(k).
- (fda.gov, accessdata.fda.gov)
- EUAs, INDs/IDEs, in vitro–only/research-use-only authorizations, animal-use approvals, or products consisting solely of dissociated cells or live microbes (e.g., standard cellular therapies or live biotherapeutics) do NOT count.